CASTILLO, GERARDO M.,LAKE, THOMAS P.,NGUYEN, BETH P.,SANDERS, VIRGINIA J.,SNOW, ALAN D.
申请号：
CA2550085
公开号：
CA2550085C
申请日:
2004.12.17
申请国别(地区):
CA
年份:
2013
代理人:
摘要：
A pharmaceutical composition that includes a peptide offormula Y-(X-aa)-Z. (X-aa) is generally an amino acid sequence selected from -Arg-Val-Ser-Val-Arg-Trp-, -Arg-Val-Ala-Val-Ile-, -His-Gly-Arg-Leu-Val-Phe-, -Leu-Ala-Phe-Val-Leu-Arg-,and -Thr-Leu-Phe-Leu-Ala-Arg-. And Y is generally an amino terminal modifyinggroup selected from an amino acid, a N-acylated amino acid, a peptide, a N-acylated peptide, and hydrogen. And Z- is carboxyl-terminal modifying groupselected from hydrogen, an amino acid, a C-amidated amino acid, a peptide, a C-amidated peptide, or an amide or hydroxyl group such as an alkyl amide, anaryl amide, or an alcohol. A composition of matter that includes at least oneof the peptide sequences -Arg-Val-Ala-Val-Ile-, -Leu-Ala-Phe-Val-Leu-Arg-, -Thr-Leu-Phe-Leu-Ala-Arg-, -Arg~Val-Ser-Val-Arg-Trp-, -His-Gly-Arg-Leu-Val-Phe-. Preferably at least one amino acid of the peptide sequence is a D- aminoacid.
